Company
Exelixis
Exelixis has 15 drugs tracked on RxWires: 1 post-market, 1 in Phase 2/3, 3 in Phase 2, 10 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Cabozantinib (XL184) 140 mg | Post-Market | Medullary Thyroid Cancer |
| Zanzalintinib | Phase 2/3 | Pancreatic Neuroendocrine Tumor (pNET) |
| Afatinib | Phase 2 | Non-small Cell Lung Carcinoma |
| XL184 | Phase 2 | Glioblastoma Multiforme |
| XL820 | Phase 2 | Gastrointestinal Stromal Tumors |
| XL309 | Phase 1 | Advanced Solid Tumor |
| XL228 | Phase 1 | Cancer |
| XL844 | Phase 1 | Cancer |
| XL019 | Phase 1 | Polycythemia Vera |
| XL888 | Phase 1 | Colorectal Adenocarcinoma |
| XL102 | Phase 1 | Neoplasm Malignant |
| XL418 | Phase 1 | Cancer |
| Cemiplimab | Phase 1 | Anaplastic Thyroid Cancer |
| Cabozantinib S-malate | Phase 1 | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation |
| XB010 | Phase 1 | Locally Advanced or Metastatic Solid Tumors |
Latest
Follow Exelixis on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.